TABLE 3.

Post-ART correlates of age at milestone attainment

Correlate	N	Mean (SD) age at walking	P-value	N	Mean (SD) age at speech	P-value
Initiated on LPV/r-ART	20	16.4 (2.7)	0.7	20	15.5 (1.9)	0.003*
NVP-ART	34	16.8 (3.6)		33	18.1 (3.2)
6-month CD4% ≥20	42	16.0 (2.7)	0.008	41	16.6 (2.9)	0.03
<20	12	18.8 (4.2)		12	18.8 (2.9)
6-month CD4 count ≥ 1500 cells/mm3	38	16.1 (2.8)	0.06	38	16.8 (3.1)	0.2
<1500 cells/mm3	16	18.0 (3.9)		15	18.1 (2.9)
6-month Plasma HIV RNA <1000 copies/mm3	29	16.2 (3.1)	0.3	29	16.5 (3.1)	0.1
≥1000 copies/mm3	25	17.2 (3.5)		24	17.8 (2.9)
6-month WAZ ≥−2	40	15.7 (2.4)	0.0003	39	16.5 (2.6)	0.009
<−2	14	19.2 (4.1)		14	18.9 (3.6)
6-month HAZ ≥−2	34	15.9 (2.9)	0.02	33	16.3 (2.8)	0.009
<−2	20	18.0 (3.5)		20	18.5 (3.1)
6-month WHZ ≥−2	47	16.2 (2.9)	0.006	46	16.9 (3.0)	0.3
<−2	7	19.8 (4.3)		7	18.3 (3.2)
6-month HCZ ≥−2	50	16.6 (3.3)	1.0	49	17.1 (3.1)	0.9
<−2	3	16.6 (1.2)		3	17.4 (4.2)
Neck control at age <4 months	21	15.2 (2.7)	0.007	21	16.2 (3.0)	0.07
≥4 months	33	17.6 (3.3)		32	17.7 (3.0)
Neck control at age <4 months†	7	15.2 (3.4)	0.06	7	17.4 (3.9)	1.0
≥4 months	23	18.1 (3.3)		22	17.4 (2.6)

^*In multivariate linear regression analyses adjusted for 6-month plasma HIV RNA level, infants who initiated LPV/r-ART had earlier speech (adj. regression coefficient, −2.58 months (95% confidence interval, −4.14, −1.02) (P=0.002) compared with infants with NVP-ART.

^†Excludes infants who had achieved neck control prior to enrollment.

ART, antiretroviral therapy; LPV/r, lopinavir-boosted-ritonavir; WAZ, weight-for-age z-score; HAZ, height-for-age z-score; WHZ, weight-for-height z-score; HCZ, head circumference-for-age z-score.